Topical Ocular Composition for Multifactor Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for dry eye disease (DED) are inadequate as they often fail to address the underlying multifactorial etiologies of the condition, leading to elusive and ineffective therapeutic outcomes for individual patients.
Innovation Solution
Development of compounds comprising anti-parasitic agents like ivermectin and H1 antagonists such as olopatadine, cetirizine, or keratolytic agents like lipoic acid, which are formulated into pharmaceutical compositions for topical application to target multiple underlying causes of DED, including demodex infestation and keratin buildup.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for dry eye disease are used, then treatment simplicity is maintained, but treatment effectiveness deteriorates due to failure to address multiple underlying causes
Solution Approach 1:
The patent combines multiple therapeutic agents (anti-parasitic agents like ivermectin, H1 antagonists like olopatadine, and keratolytic agents) into a single topical composition that can be applied once daily. This merging of multiple treatments into one formulation resolves the contradiction by maintaining treatment simplicity while improving effectiveness through comprehensive targeting of multiple disease etiologies including demodex infestation, histamine release, and keratinized material accumulation.
Solution Approach 2:
The compound formulation is designed to perform multiple functions simultaneously: anti-parasitic activity to reduce demodex mites, H1 antagonism to alleviate histamine-related symptoms, and keratolytic activity to break down keratinized material. This multi-functionality allows a single treatment to address diverse underlying causes of dry eye disease, thereby improving reliability without requiring multiple separate treatments.
2Adaptability or versatility
If single-cause treatments are used, then treatment simplicity is maintained, but adaptability to different patient etiologies deteriorates
Solution Approach 1:
The patent creates a universal treatment formulation that can effectively address multiple etiologies of dry eye disease including demodex infestation, histamine-mediated inflammation, and keratinized material accumulation. By incorporating agents with different mechanisms of action (anti-parasitic, H1 blocking, and keratolytic), the treatment becomes adaptable to various patient presentations without requiring separate formulations for different causes.
Solution Approach 2:
The formulation allows for flexible dosing and concentration adjustments to optimize effectiveness across different patient populations and disease severities. The ability to modify treatment parameters while maintaining the multi-component formulation enables adaptation to individual patient needs without increasing the fundamental complexity of the treatment approach.
Data Source
AI summary
Described herein are compositions and methods for the treatment or prevention of dermal or ocular surface disorders, such as those associated with bacterial and/or parasitic infections. Bacterial and/or parasitic infections include mites (e.g., demodex), worms, protozoa (e.g., amoeba (e.g., acanthamoeba or cryptosporidiosis)), onchocerciasis, lice, scabies, nematodes, or chlamydia. Said compositions and methods comprise compounds which demonstrate immunological, keratolytic, anti-histamine, anti-inflammatory, and/or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.